A Study of IBI3032 in Healthy Participants

Launched by FORTVITA BIOLOGICS (USA)INC. · Aug 6, 2025

Keywords

ClinConnect Summary

This clinical trial is testing a new medicine called IBI3032 in healthy adults to see if it is safe and well-tolerated when given as a single dose. The study will also look at how the body processes the medicine. About 32 healthy volunteers will take part, divided into small groups, with some receiving the medicine and others getting a placebo—a harmless, inactive substance—without anyone knowing which one they get until the study is over. This helps researchers compare effects fairly. The study is for research only and is not meant to treat any illness.

To join, participants must be healthy adults with normal lab test results and no serious health problems like heart, lung, liver, or kidney diseases. People with allergies to IBI3032 or similar medicines, or with abnormal heart tests, cannot take part. The study includes a screening process to check health and a follow-up period of 15 days after taking the dose to monitor safety. Participants can expect to spend some time at the study center for tests before and after receiving the medicine or placebo. This is an early phase study focused on safety, so no direct health benefits are expected for volunteers.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Healthy male or females, as determined by medical history
• • Have safety laboratory results within normal reference ranges
• Exclusion Criteria:
• • Have known allergies toIBI3032， glucagon-like peptide-1 (GLP-1) analogs, related compounds
• • Abnormal electrocardiogram (ECG) at screening
• • Significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders.